Supernus Initiates Phase III Clinical Trial for Epliga™ in Refractory Partial Onset Epileptic Seizures
News Dec 29, 2008
Supernus Pharmaceuticals, Inc. has announced the initiation of the pivotal Phase III clinical trial for its lead product Epliga™. The trial is a randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of Epliga for the adjunctive treatment of refractory partial onset seizures in patients with epilepsy.
Epliga is a controlled release once-per-day dosage form of oxcarbazepine that is designed to improve compliance and reduce adverse events. Earlier this year, Supernus completed a proof-of-concept study where Epliga showed significant improvement in key adverse events compared to the reference product Trileptal®.
“Initiating our Phase III trial for Epliga is a major milestone for Supernus and an important step toward addressing a significant unmet need in the treatment of epilepsy,” said Jack Khattar, president and CEO.
“We are excited about Epliga and its potential for offering epilepsy patients an effective anti-convulsant therapy with much-needed lower side effects and the convenience of once-per-day dosing. Reaching this clinical development milestone for Epliga demonstrates the significant progress Supernus has made in the three years since we started building our pipeline,” Khattar said.
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019